Leerink Partners Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $82
Press Release: ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 A.m. ET
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
Improved Revenues Required Before ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock's 25% Jump Looks Justified
Jefferies Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $80
